Clinical trial results:
Long-term Follow-up of Adult Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia Relapsed Refractory Patients Enrolled in Study 00103311

Summary

EudraCT number	2019-001575-37
Trial protocol	DE IT
Global end of trial date	07 September 2020

Results information

Result version number	v1 (current)
This version publication date	07 July 2021
First version publication date	07 July 2021

Trial information

Trial identification

Sponsor protocol code	20180138

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Amgen Inc.
Sponsor organisation address	One Amgen Center Drive, Thousand Oaks, CA, United States,
Public contact	IHQ Medical Info-Clinical Trials, Amgen (EUROPE) GmbH, MedInfoInternational@amgen.com
Scientific contact	IHQ Medical Info-Clinical Trials, Amgen (EUROPE) GmbH, MedInfoInternational@amgen.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	07 September 2020
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	07 September 2020
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The objective of this study was to conduct a one-time survival status assessment on participants who were alive at the last follow-up and still participating in the phase III study 00103311. The single output from this study effort was to generate an updated overall survival (OS) Kaplan-Meier (KM) probability estimates and KM plot.

Protection of trial subjects:

This study will comply with all applicable laws regarding subject privacy. No direct participant contact or collection of additional data from participants will occur beyond survival status assessment and blinatumomab use for participants in the standard of care arm after the conclusion of the 00103311 study by the sites. Study results will be in tabular form and aggregate analyses that omits participant identification. Any publications and reports will not include participant identifiers.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	02 December 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 5
Country: Number of subjects enrolled	Austria: 2
Country: Number of subjects enrolled	Belgium: 5
Country: Number of subjects enrolled	Bulgaria: 1
Country: Number of subjects enrolled	Canada: 7
Country: Number of subjects enrolled	Czechia: 6
Country: Number of subjects enrolled	France: 7
Country: Number of subjects enrolled	Germany: 5
Country: Number of subjects enrolled	Greece: 2
Country: Number of subjects enrolled	Ireland: 1
Country: Number of subjects enrolled	Israel: 1
Country: Number of subjects enrolled	Italy: 14
Country: Number of subjects enrolled	Poland: 2
Country: Number of subjects enrolled	Taiwan: 3
Country: Number of subjects enrolled	Turkey: 1
Country: Number of subjects enrolled	United Kingdom: 1
Country: Number of subjects enrolled	United States: 6

Country: Number of subjects enrolled	Spain: 6
Worldwide total number of subjects	75
EEA total number of subjects	51

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	67
From 65 to 84 years	8
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The study included 75 eligible participants that were alive at the last follow-up and still participating in the phase III study 00103311 when 00103311 ended earlier than planned. Data was collected from 02 December 2019 to 07 September 2020.

Pre-assignment

Screening details:

At the last follow up in study 00103311, 108 participants were alive and participating at the end of study. Of these participants, 75 were eligible for enrolment into study 20180138. Enrolment was not achieved for 33 participants due to no participation of study centres (24) or no enrolment of participants at active study centres (9).

Period 1

Period 1 title	Overall study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Standard of care (SOC) chemotherapy

Arm description:

All participants who received SOC chemotherapy in study 00103311, and who were alive at the end of 00103311 and assessed for survival status in study 20180138.

Arm type	Active comparator
Investigational medicinal product name	SOC chemotherapy
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants were administered SOC chemotherapy in study 00103311.

Arm title	Blinatumomab

Arm description:

All participants who received blinatumomab in study 00103311, and who were alive at the end of 00103311 and assessed for survival status in study 20180138.

Arm type	Experimental
Investigational medicinal product name	Blinatumomab
Investigational medicinal product code	
Other name	Blincyto®
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants received blinatumomab in study 00103311.

Number of subjects in period 1	Standard of care (SOC) chemotherapy	Blinatumomab
Started	19	56
Completed	19	56

Baseline characteristics

Reporting groups	
Reporting group title	Standard of care (SOC) chemotherapy
Reporting group description:	
All participants who received SOC chemotherapy in study 00103311, and who were alive at the end of 00103311 and assessed for survival status in study 20180138.	
Reporting group title	Blinatumomab
Reporting group description:	
All participants who received blinatumomab in study 00103311, and who were alive at the end of 00103311 and assessed for survival status in study 20180138.	

Reporting group values	Standard of care (SOC) chemotherapy	Blinatumomab	Total
Number of subjects	19	56	75
Age Categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	18	49	67
From 65-84 years	1	7	8
85 years and over	0	0	0
Age Continuous Units: years			
arithmetic mean	36.4	42.1	
standard deviation	± 16.0	± 17.5	-
Gender Categorical Units: Subjects			
Female	7	26	33
Male	12	30	42
Ethnicity Units: Subjects			
Hispanic/Latino	1	3	4
Not Hispanic/Latino	17	53	70
Unknown	1	0	1
Race Units: Subjects			
Asian	1	2	3
Other	4	1	5
White	14	53	67

End points

End points reporting groups

Reporting group title	Standard of care (SOC) chemotherapy
Reporting group description:	
All participants who received SOC chemotherapy in study 00103311, and who were alive at the end of 00103311 and assessed for survival status in study 20180138.	
Reporting group title	Blinatumomab
Reporting group description:	
All participants who received blinatumomab in study 00103311, and who were alive at the end of 00103311 and assessed for survival status in study 20180138.	

Primary: Overall Survival (OS)

End point title	Overall Survival (OS)[1]

End point description:

OS was defined as the time from randomization to the blinatumomab arm or SOC chemotherapy arm in study 00103311 until death or censoring at the last date known to be alive. Participants still alive were censored at the date they were last known to be alive.

OS was estimated using KM probability estimate. Median OS is presented as an update to the full analysis set (FAS) OS data from study 00103311, so includes data collected in study 00103311, where n = 405.

End point type	Primary

End point timeframe:

From randomization in study 00103311 up to approximately 60 months

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No formal statistical analysis was planned.

End point values	Standard of care (SOC) chemotherapy	Blinatumomab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	19[2]	56[3]		
Units: Months				
median (confidence interval 95%)	4.0 (2.9 to 5.5)	7.6 (5.6 to 9.4)		

Notes:

[2] - Median OS is presented as an update to the FAS OS data from study 00103311 where n = 134

[3] - Median OS is presented as an update to the FAS OS data from study 00103311 where n = 271

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information[1]	
Timeframe for reporting adverse events:	
0 days	
Adverse event reporting additional description:	
Serious and non-serious adverse events were not collected for this study.	
Assessment type	Non-systematic

Dictionary used	
Dictionary name	NA
Dictionary version	NA

Frequency threshold for reporting non-serious adverse events: 5 %

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.
Justification: Serious and non-serious adverse events were not collected for this study

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
29 August 2019	The following changes were made: * Added Signature page (Investigator's Agreement), amendments and updates, and list of abbreviations sections to the protocol * Clarified language regarding data collection in 'Study Population and Methods' section * Added section for safety outcome assessment * Added language regarding sensitivity analysis * Added safety reporting language and applicable safety forms since study has changed to include primary and secondary data collection * Added "Protection of Human Subjects" and "Administrative and Legal Obligations" sections to the protocol * Made editorial and administrative changes for grammatical reasons as well as for internal consistency within the protocol.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported